TRANSMITTAL FORM	Filing Date		
_		September 12, 2003	
FORM	First Named Inventor	KEIRSTEAD, HANS S.	
	Group Art Unit	1651	
(to be used for all correspondence after initial filing)	Examiner Name		
Total Number of Pages in This Submission 4	Attorney Docket Number	IRVN-009CON	
	URES (check all that apply	0	
Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Supplemental Information Disclosure Statement SB08A (2pgs.) Certified Copy of Priority Documents	signment Papers r an Application) awing(s) ensing-related Papers tition tition to Convert to a pvisional Application wer of Attorney, Revocation ange of Correspondence dress rminal Disclaimer quest for Refund 0, Number of CD(s	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) Postcard	
Incomplete Application Response to Missing Parts Remarks Remarks under 37 CFR 1.52 or 1.53		ND ACENT	
	PPLICANT, ATTORNEY, O	R AGENT	
gning Attorney/Agent CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS	LLP (4		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV 333 997 940US

i

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 333 997 940US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attorney Docket	IRVN-009CON
First Named Inventor	KEIRSTEAD, HANS S.
Application Number	10/661,105
Confirmation No.	6563
Filing Date	September 12, 2003
Group Art Unit	1651
Examiner Name	
<u> </u>	

Title: "OLIGODENDROCYTES DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR

REMYELINATION AND TREATMENT OF SPINAL

CORD INJURY"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application serial number 10/406,817, filed 4/4/2003 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. IRVN-009CON may be charged thereon.

By:

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

Date: March 10, 2004

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231 Carol L. Francis / Registration No. 36,51.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number, Complete if Known Substitute for form 1449A/PTO 10/661,105 Application Number INFORMATION DISCLOSURE Filing Date September 12, 2003 STATEMENT BY APPLICANT First Named Inventor KEIRSTEAD, HANS S. Art Unit 1651 (use as many sheets as necessary) Examiner Name Sheet of 1 Attorney Docket Number IRVN-009CON **U.S. PATENT DOCUMENTS U.S. Patent Documents** Pages, columns, lines, Cite Name of Patentee or Applicant **Date of Publication** Examiner Where Relevant Kind Code² Initials' No. of Cited Documents of Cited Document Passages or Relevant MM-DD-YYYY (if known) Figures Appear 5,766,948 Gage, et al. 06-16-1998 07-27-1999 5,928,947 Anderson, et al.

FOREIGN PATENT DOCUMENTS						
	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Datastan or	Pages, Columns, Lines,	
	No. ¹	Country Code ³ –Number ⁴ –Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶

Johe

6,040,180

03-21-2000

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
		AKIYAMA, et al. "Remyelination of the rat spinal cord by transplantation of indentified bone marrow stromal cells", J. Neurosci., (2002) Vol. 22(15): 6623-6630.			
		BAIN, et al. "Embryonic stem cells express neuronal properties in vitro", Developmental Biology, (1995) Vol. 168: 342-357.			
		BARRES, et al. "Cell death and control of cell survival in the oligodendrocyte lineage", Cell, (1992) Vol. 70(1): 31-46.			
		BILLON, et al. "Normal timing of oligodendrocyte development from genetically engineered, lineage-selectable mouse ES cells", <i>J. Cell Sci.</i> , (2002) Vol. 115: 3657-3665.			
		BJÖRKLUND, et al. "Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model", <i>PNAS</i>			
		CARPENTER, et al. "Enrichment of neurons and neural precursors from human embryonic stem cells", Exp. Neurology, (2001) Vol. 172: 383-397.			
		FREED. "Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's Disease?", PNAS, (2002) Vol. 99: 1755-1757.			
		HAJIHOSSEINI, et al. "Origin of oligodendrocytes within the human spinal cord", J. Neurosci., (1996) Vol. 16(24): 7981-7994.			
		HOLTKAMP, et al. "Chronic inflammatory demyelinating polyradiculoneuropathy with histologically proven optic neuritis", <i>Acta Neuropathol.</i> , (2001) Vol. 101: 529-531.			
		KALMAN, et al. "Spectrum and classification of inflammatory demyelinating diseases of the central nervous system", Curr. Neurology and Neurosci. Reports, (2001) Vol 1: 249-256.			

		_	
Examiner		Date	
Signature		Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year

of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/661,105 Application Number INFORMATION DISCLOSURE September 12, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor KEIRSTEAD, HANS S. Art Unit 1651 **Examiner Name** (use as many sheets as necessary) 2 Attorney Docket Number IRVN-009CON Sheet 1 of

KEIRSTEAD, et al. "Enchanced axonal regeneration following combined demyelination plus schwann cell transplantation therapy in the injured adult spinal cord", Exp. Neurol., (1999) Vol. 159(1): 225-236.
KUO, et al. "Differentiation of monkey embryonic stem cells into neural lineages", Biol. Reprod., (2002).
LIE, et al. "The adult substantia nigra contains progenitor cells with neurogenic potential", J. Neurosci., (2002) Vol. 22(15): 6639-6649.
McDONALD, et al. "Repairing the damaged spinal cord", Scientific American, (1999) Vol. 281(3): 64-73.
XIAN, et al. "A subset of ES-cell-derived neural cells marked by gene targeting", Stem Cells, (2003) Vol. 21: 41-49.
 ZHANG, et al. "Adult brain retains the potential to generate oligodendroglial progenitors with extensive myelination capacity", <i>Proc. Natl. Acad. Sci. USA</i> , (1999) Vol. 96: 4089-4094.

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year

of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.